Drug Profile
Research programme: depression therapy - Neurologix
Latest Information Update: 06 Jun 2014
Price :
$50
*
At a glance
- Originator Cornell University
- Developer Cornell University; Neurologix
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 16 Mar 2012 Discontinued - Preclinical for Major depressive disorder in USA (Parenteral)
- 28 Apr 2011 This programme is in active development
- 27 Oct 2009 Preclinical trials in Depression in USA (Parenteral)